The Spanish publication Médicos y Pacientes featured UEMO’s General Assembly. The Spanish delegation was represented by Dr. Hermenegildo Marcos, who is also the national representative of Rural Primary Care physicians of the General Council of Official Medical Associations. Dr. Mary McCarthy, UEMO Vice-President, presented the preliminary results of the survey on the remuneration of the […]

Non-communicable diseases represented 80% of the EU’s disease burden before the COVID-19 pandemic. Trying to address this challenge, the European Commission is calling for best practices focusing on prevention and management of non-communicable diseases: cardiovascular diseases, diabetes, chronic respiratory diseases, mental health and neurological disorders, and health determinants, as part of the ‘Healthier together’ – […]

As of Monday 31 January,  the assessment and supervision of clinical trials throughout the EU will be harmonised, notably via a Clinical Trials Information System (CTIS) run by the European Medicines Agency. On this date the Regulation on Clinical Trials will enter into application. This Regulation will improve conducting clinical trials in the EU, with the highest standards of safety for participants […]

UEMO, a member of EMA’s Healthcare Professionals Working Party and of EMA’s Covid-19 Task Force, has been asked by EMA to disseminate the safety information of the first antiviral for ambulatory use in Covid-19 patients, Paxlovid, approved on 27 January for use in the European Union. We have been asked in particular to highlight the  […]

On January 14, the European Commission adopted the second EU4Health work programme. In 2022, the EU4Health will continue to invest in building stronger, more resilient health systems and pave the way for the European Health Union. With a budget of over €835 million, the new work programme will provide an unparalleled level of EU investment in health and ensure ambitious […]

UEMO is pleased to be part of the distinguished 38 stakeholders that have bene interacting with the European Medicines Agency (EMA) over the past 10 years. EMA recognises that healthcare professionals are present in all aspects of medicines regulation as members of committees and expert groups, in addition to the specialists that are invited on […]

On December 13, the European Commission adopted the Regulation on Health Technology Assessment (HTA), a deliverable of the EU Pharmaceutical Strategy. The new rules will allow vital and innovative health technologies – such as innovative medicines, certain medical devices, medical equipment and prevention and treatment methods – to be more widely available. The Regulation will […]

On 9 December, Parliament’s Special Committee on Beating Cancer adopted its final proposals on how to strengthen the EU’s role in the fight against cancer. They include the following: 1. Taking stronger EU action to address key risk factors and social determinants of cancer 2. Extending screening schemes and launching an EU platform of national […]

Today, the European Commission published a study on medicines shortages in the EU, which has been requested by stakeholders, the European Parliament and the Council. Shortages present a significant problem for the quality and continuity of patient care, and can also have economic consequences. Though a number of actions have been launched in recent years […]